Scorpius Holdings reports FY2023 net loss $45.2M, Q4 revenue up 570% sequentially, going concern warning

Scorpius Holdings, Inc.

2024-Q1 EPS reported -$0.16 revenue$3,513,948

FY2023 contract revenue $6.6M (vs $0.1M in 2022); Q4 2023 revenue $4.8M, a 570% sequential increase from Q3.
Net loss attributable to Scorpius $45.2M ($1.74 per share) vs $43.4M ($1.70) in 2022.
Cash and equivalents $2.4M as of December 31, 2023.
Auditor includes going concern opinion due to recurring losses and lack of significant revenue or positive cash flows.
Management expects to become cash flow positive by early 2025; over $20M in contract bookings recorded.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Scorpius Holdings, Inc. reported the year ended December 31, 2023 results: revenue $6.6 million of contract revenue, $0.3 million of National Institutes of Health grant revenue, and $0.1 million of royal, net income approximately $45.2 million, or ($1.74) per basic and diluted share, EPS ($1.74) per basic and diluted share.

Period: the year ended December 31, 2023
Revenue: $6.6 million of contract revenue, $0.3 million of National Institutes of Health grant revenue, and $0.1 million of royal
Net income: approximately $45.2 million, or ($1.74) per basic and diluted share
EPS: ($1.74) per basic and diluted share
Result: reported results

Exact text from the filing

For the year ended December 31, 2023, the Company recognized $6.6 million of contract revenue, $0.3 million of National Institutes of Health grant revenue, and $0.1 million of royalty revenue from continuing operations.

View on SEC.gov

292 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001079973-24-000604

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.